Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.56 |
| ▸ | NAAA | Q02083 | 2/20 | 0.55 |
| ▸ | FAAH | O00519 | 3/20 | 0.54 |
| ▸ | METAP2 | P50579 | 1/20 | 0.53 |
| ▸ | PRCP | P42785 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22260401 | 1.00 | CASP2 (0.56) | CASP2NAAAFAAHMETAP2PRCP | |
| SCHEMBL8847500 | 0.91 | CASP2 (0.59) | CASP2NAAAMETAP2PRCPEPHX1 | |
| SCHEMBL24193475 | 0.91 | CASP2 (0.59) | CASP2NAAAMETAP2PRCPEPHX1 | |
| SCHEMBL24429263 | 0.91 | FAAH (0.54) | CASP2NAAAFAAHMETAP2PRCP | |
| SCHEMBL28340973 | 0.89 | CASP2 (0.61) | CASP2NAAAFAAHMETAP2PRCP | |
| SCHEMBL8847507 | 0.89 | CASP2 (0.56) | CASP2NAAAMETAP2PRCPEPHX1 | |
| SCHEMBL5496547 | 0.86 | EPHX1 (0.65) | NAAAMETAP2EPHX1EPHX2 | |
| SCHEMBL8847821 | 0.84 | ALDH1A1 (0.56) | CASP2NAAAEPHX1EPHX2 | |
| SCHEMBL12792145 | 0.84 | CASP2 (0.54) | CASP2NAAAMETAP2PRCPEPHX1 | |
| SCHEMBL7543330 | 0.83 | GNAI3 (0.53) | CASP2FAAHEPHX1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CASP2 406/4885NAAA 1342/4885FAAH 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.